{"id":"placebo-in-combination-with-pembrolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (from Pembrolizumab)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL3137343","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In this Phase 3 trial design, placebo is administered alongside Pembrolizumab to establish efficacy and safety of the combination regimen. Pembrolizumab works by inhibiting PD-1 on T cells, preventing tumor cells from suppressing immune attack. The placebo arm allows for controlled comparison of the active combination therapy.","oneSentence":"Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:39.547Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication under investigation in Phase 3 trial (specific indication not provided)"}]},"trialDetails":[{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT06788990","phase":"PHASE2, PHASE3","title":"FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC","status":"RECRUITING","sponsor":"Bicara Therapeutics","startDate":"2025-01-28","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":650},{"nctId":"NCT07218380","phase":"PHASE3","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-12","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis","enrollment":450},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07063745","phase":"PHASE2, PHASE3","title":"A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-02","conditions":"Metastatic Non-small Cell Lung Cancer With MTAP Deletion","enrollment":590},{"nctId":"NCT06345729","phase":"PHASE3","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-24","conditions":"Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT04657991","phase":"PHASE3","title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Melanoma","enrollment":257},{"nctId":"NCT07098988","phase":"PHASE2","title":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-08-01","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":107},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT06236438","phase":"PHASE2, PHASE3","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-04-10","conditions":"Non-Small Cell Lung Cancer","enrollment":840},{"nctId":"NCT03820986","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-12","conditions":"Malignant Melanoma","enrollment":674},{"nctId":"NCT03713593","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":794},{"nctId":"NCT03898180","phase":"PHASE3","title":"Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-06","conditions":"Urothelial Carcinoma","enrollment":505},{"nctId":"NCT04619797","phase":"PHASE2, PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":542},{"nctId":"NCT07365319","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-05-18","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC","enrollment":750},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT04889118","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-14","conditions":"Malignant Melanoma","enrollment":131},{"nctId":"NCT05352672","phase":"PHASE3","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-07-14","conditions":"Melanoma","enrollment":1546},{"nctId":"NCT06093425","phase":"PHASE3","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","startDate":"2026-06-30","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer","enrollment":820},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT06295731","phase":"PHASE2, PHASE3","title":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2024-05-14","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":410},{"nctId":"NCT06472076","phase":"PHASE3","title":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-06-10","conditions":"Lung Cancer, Non-Small Cell","enrollment":88},{"nctId":"NCT02752074","phase":"PHASE3","title":"A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-06-21","conditions":"Melanoma","enrollment":706},{"nctId":"NCT03361865","phase":"PHASE3","title":"Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-04","conditions":"UC (Urothelial Cancer)","enrollment":93},{"nctId":"NCT03322540","phase":"PHASE2","title":"Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-15","conditions":"Lung Cancer","enrollment":154},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT06082167","phase":"PHASE2, PHASE3","title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2024-06-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":600},{"nctId":"NCT02546986","phase":"PHASE2","title":"Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-10-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":100},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT04746924","phase":"PHASE3","title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-06-08","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":662},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT05608291","phase":"PHASE3","title":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-16","conditions":"Melanoma","enrollment":1564},{"nctId":"NCT06749925","phase":"PHASE3","title":"Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01","conditions":"Glioblastoma","enrollment":186},{"nctId":"NCT05913388","phase":"PHASE2","title":"GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2024-02-29","conditions":"Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT06823323","phase":"NA","title":"The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT04909034","phase":"NA","title":"A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Microbio Co Ltd","startDate":"2021-08-20","conditions":"NSCLC Stage IIIB~IV","enrollment":15},{"nctId":"NCT03425643","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-24","conditions":"Non-small Cell Lung Cancer","enrollment":797},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT06601335","phase":"PHASE3","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":510},{"nctId":"NCT03189719","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-07-25","conditions":"Esophageal Neoplasms","enrollment":749},{"nctId":"NCT04428333","phase":"PHASE3","title":"Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2020-08-12","conditions":"Neoplasms, Head and Neck","enrollment":117},{"nctId":"NCT06099418","phase":"PHASE2","title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","status":"WITHDRAWN","sponsor":"Nykode Therapeutics ASA","startDate":"2024-04-18","conditions":"HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer","enrollment":""},{"nctId":"NCT04128696","phase":"PHASE3","title":"Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-11-21","conditions":"Neoplasms, Head and Neck","enrollment":315},{"nctId":"NCT06472583","phase":"PHASE2","title":"Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2024-04-11","conditions":"Breast Cancer","enrollment":78},{"nctId":"NCT04622007","phase":"PHASE2","title":"Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Effector Therapeutics","startDate":"2021-06-02","conditions":"Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT05705466","phase":"PHASE1, PHASE2","title":"Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2023-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05791097","phase":"PHASE3","title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT05809895","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-15","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT04987996","phase":"PHASE2","title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","status":"WITHDRAWN","sponsor":"Providence Health & Services","startDate":"2023-07-01","conditions":"Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT02263508","phase":"PHASE3","title":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-12-08","conditions":"Melanoma","enrollment":713},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT03066778","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-05-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":453},{"nctId":"NCT05429697","phase":"PHASE2, PHASE3","title":"Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"SMT bio Co., Ltd.","startDate":"2022-06-09","conditions":"Biliary Tract Cancer","enrollment":128},{"nctId":"NCT04265534","phase":"PHASE2","title":"KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","status":"TERMINATED","sponsor":"Calithera Biosciences, Inc","startDate":"2020-07-24","conditions":"Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung","enrollment":40},{"nctId":"NCT02130466","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-29","conditions":"Melanoma, Solid Tumors","enrollment":184},{"nctId":"NCT03322566","phase":"PHASE2","title":"A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-01-09","conditions":"Lung Cancer","enrollment":233},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT03881111","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-21","conditions":"Esophageal Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo in combination with Pembrolizumab","genericName":"Placebo in combination with Pembrolizumab","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses. Used for Indication under investigation in Phase 3 trial (specific indication not provided).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}